T-Cells

#Biotherapeutics #Cell therapy #Gene editing #Immunotherapy #T-Cells

Atara Biotherapeutics’ plans to tackle MS with Epstein-Barr Virus

Over the last decade, groundbreaking chimeric antigen receptor (CAR) T-cell immunotherapies have become a well-established cancer treatment modality. Clinical research continues to demonstrate the encouraging potential this approach holds for treating a wide array of conditions while increasing safety, tolerability, and efficiency in manufacturing. Atara Biotherapeutics, a California-based biotechnology company,… Read More

#Editor's Choice #Exclusive Content #News #Opinion

#Cancer research #Clinical trials #Drug discovery #Oncology #T-Cells #Tumours

HOOKIPA advances to Phase II trials for treatment of head and neck cancer 

HOOKIPA Pharma is advancing HB-201 to Phase II to be evaluated in combination with pembrolizumab as first or second-line treatment for Human Papillomavirus Positive 16 (HPV16+) squamous cell head and neck cancers (HNSCC).   Interim Phase I data in heavily pre-treated patients continue to show HB-200 monotherapy (both… Read More

#News

#Covid-19 #Drug design #Drug discovery #Immunology / Virology & Vaccines #Research #T-Cells

T-cell discovery could lead to new type of Covid-19 vaccines 

A study has found that some people are able to clear the Covid-19 virus quickly due to strong immune response from existing T-cells, which could lead to a new generation of vaccine development.   In a study published in Nature, researchers found that individuals with potential exposure to… Read More

#Covid-19 #News #Trending News

#Immuno-oncology #T-Cells #Therapeutics

T-Cypher Bio separates from Orbit Discovery to build a pipeline of TCR therapeutics

T-Cypher Bio, a biotech company pioneering a novel approach to (T cell receptor) TCR therapeutics has separated from Orbit Discovery to focus on developing a functional, high-throughput, bead-display platform to select therapeutically relevant targets and identify potent, target-specific TCRs for the treatment of solid tumours and other indications. The formation… Read More

#News

#Antibody #Covid-19 #Immunology / Virology & Vaccines #T-Cells

Oxford vaccine stimulates broad antibody and T cell functions

Researchers from the University of Oxford have published further data from the Phase I/II clinical trials of the ChAdOx1 nCoV-19 coronavirus vaccine, evidencing the decision to move to a two-dose regimen in ongoing Phase III trials, and how ChAdOx1 nCov-19 is induces broad antibody and T cell functions. These findings… Read More

#Covid-19 #Editor's Choice #News #Trending News

#CAR-T #T-Cells

Flow cytometry in immuno-oncology: tools to evaluate potential drugs

Researchers are continually looking for processes and technology that give them the edge scientifically or commercially. If you are a biotech scientist interested in reversing or overcoming the state of T-cell exhaustion, this webinar will be beneficial to your work. Quantifying T cell exhaustion: An insight into BiTE antibodies… Read More

#News

#CAR-T #T-Cells

Quantifying T cell exhaustion: An insight into BiTE antibodies and CAR-T cells

This webinar looks at T cell exhaustion. This is recognised as a major challenge in the development of immuno-oncology therapies. Used to describe the loss of effector function due to chronic antigen exposure, it commonly occurs within the tumour microenvironment. This impairs the T cells’ ability to effectively eradicate cancerous… Read More

Webinar date:
Brought to you by Sartorius
#Webinars